Selected Publications

A universal model for drug-receptor interactions

Menezes F, Wahida A, Fröhlich T, Grass P, Zaucha J, Napolitano V, Siebenmorgen T, Pustelny K, Barzowska-Gogola A, Rioton S, Didi K, Bronstein M, Czarna A, Hochhaus A, Plettenburg O, Sattler M, Nissen-Meyer J, Conrad M, Kurzrock R, Popowicz GM

bioRxiv 2025.08.01.668090; doi: https://doi.org/10.1101/2025.08.01.668090.

Structural perspective on the design of selective DYRK1B inhibitors

Grygier P, Pustelny K, Menezes F, Jemiola-Rzeminska M, Suder P, Dubin G, Czarna A

Int J Biol Macromol. 2025 Nov;330(Pt 3):148124. doi: 10.1016/j.ijbiomac.2025.148124.

Development of selective ssDNA micro-probe for PD1 detection as a novel strategy for cancer imaging

Malicki S, Czarna A, Żyła E, Pucelik B, Gałan W, Chruścicka B, Kamińska M, Sochaj-Gregorczyk A, Magiera-Mularz K, Wang J, Winiarski M, Benedyk-Machaczka M, Kozieł J, Dubin G, Mydel P.

Sci Rep. 2024; 14: 28652. doi: 10.1038/s41598-024-74891-7.

Exploring Novel GSK-3β Inhibitors for Anti-Neuroinflammatory and Neuroprotective Effects: Synthesis, Crystallography, Computational Analysis, and Biological Evaluation

Góral I, Wichur T, Sługocka E, Grygier P, Głuch-Lutwin M, Mordyl B, Honkisz-Orzechowska E, Szałaj N, Godyń J, Panek D, Zaręba P, Sarka A, Żmudzki P, Latacz G, Pustelny K, Bucki A, Czarna A, Menezes F, Więckowska A.

ACS Chem Neurosci. 2024 Sep 4;15(17):3181-3201. doi: 10.1021/acschemneuro.4c00365. Epub 2024 Aug 19.

Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics

Pustelny K, Grygier P, Barzowska A, Pucelik B, Matsuda A, Mrowiec K, Slugocka E, Popowicz GM, Dubin G, Czarna

Sci Rep. 2023 Oct 23;13(1):18114. doi: 10.1038/s41598-023-44810-3

DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets

Pucelik B, Barzowska A, Czarna A.

PLoS One. 2023 May 17;18(5):e0285208. doi: 10.1371/journal.pone.0285208. eCollection 2023

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective

Grygier P, Katarzyna Pustelny K, Dubin G, Czarna A.

Med Chem. 2023 Mar 23;66(6):4009-4024. doi: 10.1021/acs.jmedchem.2c01887. Epub 2023 Mar 8

Diabetic Kinome Inhibitors - A New Opportunity for β-Cells Restoration

Pucelik B, Barzowska A, Dąbrowski JM, Czarna A.

Int. J. Mol. Sci. 2021, 22(16), 9083. doi: 10.3390/ijms22169083

DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis

Barzowska A, Pucelik B, Pustelny K, Matsuda A, Martyniak A, Stępniewski J, Maksymiuk A, Dawidowski M, Rothweiler U, Dulak J, Dubin G, Czarna A.

Cells. 2021 Aug 31;10(9):2263. doi: 10.3390/cells10092263

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors

Czarna A, Wang J, Zelencova D, Liu Y, Deng X, Choi HG, Zhang T, Zhou W, Chang JW, Kildalsen H, Seternes OM, Gray NS, Engh RA, Rothweiler U.

J Med Chem. 2018 Sep 13;61(17):7560-7572. doi: 10.1021/acs.jmedchem.7b01847